Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008).

Literature DB >> 20534798

Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008).

Shawn A Messer¹, Ronald N Jones, Gary J Moet, Jeffrey T Kirby, Mariana Castanheira.

Abstract

The SENTRY Antimicrobial Surveillance Program regularly monitors global susceptibility rates for a spectrum of both novel and established antifungal agents. Anidulafungin and the other echinocandins displayed sustained, excellent activity against Candida spp. and Aspergillus fumigatus, with >or=98% of MIC results at <or=2 microg/ml. Six yeast isolates (all Candida glabrata) showing caspofungin MIC values of >or=0.5 microg/ml were further analyzed for potential fks hot spot (HS) mutations; three isolates had confirmed mutations in the fks1 HS1 region (S645P), and three exhibited mutations in the fks2 HS1 region (S645F and S645P).

Entities: Chemical Mutation Species

Mesh：

Substances：

Year: 2010 PMID： 20534798 PMCID： PMC2916586 DOI： 10.1128/JCM.00328-10

Source DB: PubMed Journal: J Clin Microbiol ISSN： 0095-1137 Impact factor: 5.948

14 in total

Review 1. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.

Authors: Elias K Spanakis; George Aperis; Eleftherios Mylonakis
Journal: Clin Infect Dis Date: 2006-09-08 Impact factor: 9.079

2. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.

Authors: M A Pfaller; D J Diekema; L Ostrosky-Zeichner; J H Rex; B D Alexander; D Andes; S D Brown; V Chaturvedi; M A Ghannoum; C C Knapp; D J Sheehan; T J Walsh
Journal: J Clin Microbiol Date: 2008-06-25 Impact factor: 5.948

Review 3. Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery.

Authors: R A Hajjeh; M E Brandt; R W Pinner
Journal: Epidemiol Rev Date: 1995 Impact factor: 6.222

4. The epidemiology of hematogenous candidiasis caused by different Candida species.

Authors: D Abi-Said; E Anaissie; O Uzun; I Raad; H Pinzcowski; S Vartivarian
Journal: Clin Infect Dis Date: 1997-06 Impact factor: 9.079

5. Initial results from a longitudinal international surveillance programme for anidulafungin (2003).

Authors: Shawn A Messer; Jeffrey T Kirby; Helio S Sader; Thomas R Fritsche; Ronald N Jones
Journal: J Antimicrob Chemother Date: 2004-11-25 Impact factor: 5.790

6. Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds.

Authors: A Espinel-Ingroff; A Fothergill; M Ghannoum; E Manavathu; L Ostrosky-Zeichner; M A Pfaller; M G Rinaldi; W Schell; T J Walsh
Journal: J Clin Microbiol Date: 2007-05-02 Impact factor: 5.948

7. In vitro activity of anidulafungin against selected clinically important mold isolates.

Authors: Zekaver Odabasi; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; Luis Ostrosky-Zeichner
Journal: Antimicrob Agents Chemother Date: 2004-05 Impact factor: 5.191

8. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007).

Authors: Shawn A Messer; Gary J Moet; Jeffrey T Kirby; Ronald N Jones
Journal: J Clin Microbiol Date: 2009-04-22 Impact factor: 5.948

9. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.

Authors: Marie Desnos-Ollivier; Stéphane Bretagne; Dorothée Raoux; Damien Hoinard; Françoise Dromer; Eric Dannaoui
Journal: Antimicrob Agents Chemother Date: 2008-06-30 Impact factor: 5.191

10. Acquired resistance to echinocandins in Candida albicans: case report and review.

Authors: Marie-Thérèse Baixench; Naji Aoun; Marie Desnos-Ollivier; Dea Garcia-Hermoso; Stéphane Bretagne; Sandrine Ramires; Christophe Piketty; Eric Dannaoui
Journal: J Antimicrob Chemother Date: 2007-04-27 Impact factor: 5.790

14 in total

1. In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network.

Authors: Shawn R Lockhart; Alicia J Zimbeck; John W Baddley; Kieren A Marr; David R Andes; Thomas J Walsh; Carol A Kauffman; Dimitrios P Kontoyiannis; James I Ito; Peter G Pappas; Tom Chiller
Journal: Antimicrob Agents Chemother Date: 2011-06-13 Impact factor: 5.191

2. In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species.

Authors: Barbara Fiori; Brunella Posteraro; Riccardo Torelli; Mario Tumbarello; David S Perlin; Giovanni Fadda; Maurizio Sanguinetti
Journal: Antimicrob Agents Chemother Date: 2011-03-21 Impact factor: 5.191

3. Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo.

Authors: Keunsook K Lee; Donna M Maccallum; Mette D Jacobsen; Louise A Walker; Frank C Odds; Neil A R Gow; Carol A Munro
Journal: Antimicrob Agents Chemother Date: 2011-10-10 Impact factor: 5.191

4. Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance.

Authors: Santosh K Katiyar; Ana Alastruey-Izquierdo; Kelley R Healey; Michael E Johnson; David S Perlin; Thomas D Edlind
Journal: Antimicrob Agents Chemother Date: 2012-10-01 Impact factor: 5.191

5. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009.

Authors: Michael A Pfaller; Gary J Moet; Shawn A Messer; Ronald N Jones; Mariana Castanheira
Journal: Antimicrob Agents Chemother Date: 2010-11-29 Impact factor: 5.191

6. Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida.

Authors: Michael A Pfaller; Mariana Castanheira; Daniel J Diekema; Shawn A Messer; Ronald N Jones
Journal: J Clin Microbiol Date: 2011-09-07 Impact factor: 5.948

7. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.

Authors: Michael A Pfaller; Frederick Duncanson; Shawn A Messer; Gary J Moet; Ronald N Jones; Mariana Castanheira
Journal: Antimicrob Agents Chemother Date: 2011-08-15 Impact factor: 5.191